Cytomegalovirus (CMV) antigenemia was directly detected in polymorphonuclear leukocytes (PMNLs) from transplant recipients by using flow cytometry (FC). Two fixation and permeabilization methods and seven anti-CMV monoclonal antibodies (MAbs) were evaluated. 1C3, SL20, and NEA-9221 MAbs were more efficacious. The antigenemia detection threshold of FC was 0.05% positive PMNLs, and percentages correlated well with DNA viral load and the appearance of clinical symptoms.
Cytomegalovirus (CMV) infection is a frequent complication following transplantation and is one of the commonest opportunistic infections in AIDS patients. Among the different techniques used to confirm active infection, determination of pp65 antigenemia has the advantage of directly quantifying the viral load, which generally correlates well with CMV disease (5, 6, 14, 21, 22) . However, the detection of positive cells is subjective and demands very careful and time-consuming microscopic observation (5) . One approach to overcome these major hurdles might be to automate immunofluorescence detection. Conclusive trials have been carried out with image cytometry (12, 16) , requiring highly specialized equipment and still taking considerable time. Another approach is flow cytometry (FC), which was successfully adapted to CMV antigen detection in some reported studies (15) , although most of these have been carried out on cells infected in vitro or on cells isolated from bronchoalveolar lavage samples (2) .
We present here the results of a method for the direct quantification of CMV antigenemia in polymorphonuclear leukocytes (PMNLs) by FC (antigenemia FC), which were compared with those of techniques for determining viremia and qualitative and quantitative DNAemia.
Sixty EDTA blood samples, obtained from 25 renal and 8 bone marrow transplant CMV-seropositive recipients, were evaluated by antigenemia FC. All specimens were processed within 4 h after collection. Leukocytes (5 ϫ 10 5 ) obtained after erythrocyte lysis or MRC-5 fibroblasts were fixed and permeabilized by two technical procedures run in parallel. In the paraformaldehyde-Tween method (19) , the cell pellet was resuspended in 1% paraformaldehyde (Mercks, Nogent sur Marne, France) with 0.2% Tween 20 (Sigma, Saint-Quentin en Yvelines, France) and incubated overnight at 4°C. In the paraformaldehyde-methanol method (18) , the cell pellet was sequentially incubated with 1% paraformaldehyde for 15 min at 4°C, washed once in phosphate-buffered saline, resuspended in cold 80% methanol, and kept at Ϫ20°C overnight.
Fixed and permeabilized cells were washed and incubated for 45 min at 37°C with a saturating amount (0. All incubation and wash steps were done in phosphate-buffered saline supplemented with 20% human AB serum in order to obtain Fc receptor saturation and thus limit nonspecific binding. Several controls were run in parallel (9): PMNLs from patients without active infections and mock-infected MRC-5 fibroblast monolayers served as negative controls, and MRC-5 fibroblast monolayers cultured for 4 days with the AD169 reference strain (at a multiplicity of infection between 0.01 and 0.1) served as positive controls.
Samples were analyzed on a FACSCalibur flow cytometer (Becton Dickinson, Mountain View, Calif.). At least 50,000 PMNLs or 10,000 MRC-5 fibroblasts were gated by light scatter (PMNL gates were assessed for accuracy when appropriate by using CD15 staining) and collected in a list mode manner. Data analysis was performed with Cell Quest software (Becton Dickinson). The percentages of positive cells and the mean fluorescence intensities were determined on forward side scatter versus FITC fluorescence dot plots (for PMNLs) or FITC fluorescence histograms (for MRC-5 fibroblasts), using a region defined according to isotype control analysis.
For all patients, viremia (by the shell vial assay [7] ) and qualitative DNAemia in leukocytes were also determined in parallel, as previously described (10) . In some of these pa-tients, the DNA viral load in leukocytes was also quantified (11), using the commercially available CMV hybrid capture system (Murex, Chatillon, France) according to the manufacturer's recommendations.
No nonspecific labeling, with the exception of MAb NEA 9220, was noted when mock-infected MRC-5 fibroblasts were incubated with anti-CMV MAbs (data not shown) or when isotype controls were run on AD169-infected MRC-5 fibroblasts (Fig. 1) . Six of the seven MAbs recognized CMV antigens on infected MRC-5 fibroblasts (Fig. 1) , and the percentages of positive cells were higher with MAbs detecting immediate-early antigens. Both methods of fixation and permeabilization yielded similar results (data not shown). Our results agreed with those previously reported for E13 and NEA-9221, with the exception of NEA-9220, which exhibited nonspecific staining (20) . Optimizing cytometry protocols is a very important step in allowing detection of viral antigens present at low frequencies, i.e., 10 2 to 10 6 (12), and located intracellularly in leukocytes. Both selected techniques for PMNL preparation used reagents which provide good stabilization of permeabilized membranes and increase the indirect fluorescence of intranuclear antigen (17, 18) . To allow accurate and reproducible quantification of positive cells present at a concentration of 0.05%, at least 50,000 events have to be analyzed (1, 8) .
The results obtained in 20 samples from 10 renal transplant recipients with active infections confirmed by laboratory tests (i.e., positive DNAemia associated or not with positive viremia) (Table 1 ) demonstrate the superiority of MAbs NEA-9221, 1C3, and SL20 and also the greater effectiveness of the paraformaldehyde-methanol method. With the other MAbs, no labeling was obtained, with the exception of the pooled C10-C11, which was only found to be positive in 10 of 20 specimens. No nonspecific labeling occurred on PMNLs from infected patients (Table 1 and Fig. 2 ) with isotype controls. The mean fluorescence intensity of these three antibodies on infected PMNLs showed a bimodal expression in the case of MAb SL20, a raised unimodal expression in the case of NEA 9221, and a low unimodal expression in the case of 1C3 (Fig.  2) . The reproducibility of our method ( Table 2 ) was evaluated in two separate experiments (each in triplicate), using samples from three infected patients. The standard deviation was consistently below 0.05%, whichever leukocyte preparation method was used. Increasing the number of PMNLs analyzed to 150,000 events yielded the same percentages of positive cells as 50,000 events did (data not shown). For PMNLs from patients without active infections (40 specimens), the percentage of positive cells, labeled with 1C3 or SL20 MAb, was below 0.03%, corresponding to the background fluorescence obtained with isotype controls (Table 1) . For MAb NEA-9221, a weak labeling (Table 1) was sometimes observed, which was not related to the subclass, IgG2a, of this antibody (Fig. 2) .
The most useful antibody is therefore MAb 1C3, confirming the advantage of detecting late antigens (3, 5) . MAb 1C3 is also used in slide detection of antigenemia, as is the C10-C11 pool (4, 6, 13, 14, 16) . The weak labeling obtained with this pool on PMNLs is quite surprising; both these MAbs are directed against pp65, have the same isotype, and reacted similarly with infected fibroblasts (Fig. 1) . Differences between 1C3 and C10-C11 could therefore be explained by recognition of distinct epitopes on pp65 and/or a better penetration of 1C3 into the permeabilized PMNLs. The levels of antigen expression in PMNLs from patients with active infections (maximum proportion of cells expressing CMV antigen ϭ 1.5%) correspond to levels reported for the slide method (5, 6, 21) . Much higher percentages of peripheral blood lymphocytes expressing CMV antigens had been reported previously, but these data concern peripheral blood mononuclear cells (15) . For our method, the threshold of positivity was established at 0.05% for the MAbs 1C3 and SL20 and at 0.10% for MAb NEA-9221, according to reproducibility test results (Table 2 ) and data from patients without active infections ( Table 1 ). The sensitivity of antigenemia FC is therefore lower than that which can theoretically be obtained by using the slide method. Most authors have shown that low levels of antigens very rarely indicate progressive disease (5, 6, 13) , especially in solid-organ transplant recipients when counts of positive cells do not exceed 50 per 100,000 PMNLs, a level which corresponds to our detection threshold (i.e., 0.05%). Antigenemia FC was evaluated in a clinical situation for 14 of 20 positive specimens, taken from 5 renal transplant recipients for whom a prospective follow-up for CMV infection had been carried out (Table 3) . Progressive intensification of antigenemia was observed with all three MAbs selected, and in patient 5 a distinct diminution was seen after ganciclovir initiation. There was generally good agreement between the degree of DNA load and the level of antigenemia detected by FC, as assessed with MAbs 1C3 and SL20, except for patient 3. With these two MAbs, the highest percentages were seen with patient 1, who had severe CMV disease (pneumonitis). With MAb NEA-9221, antigenemia detected by FC correlates less well with the DNA load, suggesting that viral antigen expression may vary according to the stage of infection or of the disease. Studies on a larger scale will perhaps allow this point to be clarified. The sensitivity of detection by FC analysis proved adequate in all patients, including patient 2, for whom viremia detection was consistently negative (in spite of the fact that samples were cultured in six wells).
Quantification of antigenemia, especially when 1C3 MAb is used, can therefore be adapted to direct detection by FC. Since it is less sensitive than the slide method, our method is probably not suitable for very early detection of active infection, but it would seem promising for the quantification of the viral load in patients already screened by a method such as PCR. Studies on a larger scale are in progress, which will allow more detailed assessment of the clinical utility of antigenemia FC. 
